Literature DB >> 7068046

Clinical detection of the hepatic lesion of pericentral sclerosis in chronic alcoholics.

Y Kaku, Y Hasumura, J Takeuchi.   

Abstract

It has been shown that a specific liver lesion--that is, pericentral sclerosis associated with pericellular fibrosis--is the precursor of alcoholic liver sclerosis. It is, however, difficult to diagnose this hepatic lesion in chronic alcoholics, using only clinical data without liver biopsy. To investigate the possibility of a clinical test reflecting the presence of this hepatic lesion, ethanol (0.75 g/kg body weight) was given orally to chronic alcoholics, and serum glycoprotein levels (prealbumin, alpha HS glycoprotein, haptoglobin, alpha 2-macroglobulin) were measured before and six hours after. Chronic alcoholics were divided into three groups according to the histological findings in the liver at the time of study. Group I (alcoholic fatty liver or non-specific change) consisted of seven cases without pericentral sclerosis. Group II (alcoholic hepatic fibrosis or alcoholic hepatitis) consisted of five cases with pericentral sclerosis and pericellular fibrosis. Group III consisted of five cases with alcoholic liver cirrhosis. After the ethanol administration, serum glycoprotein levels decreased significantly in group I (P less than 0.05), whereas they increased in group II and group III. Their alternative ratios (see text) apparently differed (P less than 0.005) between group I and group II, and between group I and group III. These results indicate that the determination of serum glycoprotein levels before and after oral ethanol administration is useful way of discriminating alcoholic patients with hepatic pericentral sclerosis and pericellular fibrosis from alcoholics without such lesions.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7068046      PMCID: PMC1419632          DOI: 10.1136/gut.23.3.215

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

1.  Evidence that acetaldehyde irreversibly impairs glycoprotein metabolism in liver slices.

Authors:  M F Sorrel; D J Tuma; A J Barak
Journal:  Gastroenterology       Date:  1977-11       Impact factor: 22.682

Review 2.  Effects of alcohol on hepatic metabolism: selected aspects.

Authors:  M F Sorrell; D J Tuma
Journal:  Clin Sci (Lond)       Date:  1979-12       Impact factor: 6.124

3.  Quantitative immunoelectrophoresis of serum proteins in cryptogenic cirrhosis, alcoholic cirrhosis and active chronic hepatitis.

Authors:  I M Murray-Lyon; H G Clarke; K McPherson; R Williams
Journal:  Clin Chim Acta       Date:  1972-06       Impact factor: 3.786

4.  Serum enzyme changes as evidence of liver reaction to oral alcohol.

Authors:  D M Goldberg; C Watts
Journal:  Gastroenterology       Date:  1965-09       Impact factor: 22.682

5.  Impairment of glycoprotein synthesis in acute ethanol intoxication in rats.

Authors:  S Mookerjea; A Chow
Journal:  Biochim Biophys Acta       Date:  1969-06-17

6.  Selective impairment of glycoprotein metabolism by ethanol and acetaldehyde in rat liver slices.

Authors:  M F Sorrell; D J Tuma
Journal:  Gastroenterology       Date:  1978-08       Impact factor: 22.682

7.  Alcoholic hepatomegaly: accumulation of protein in the liver.

Authors:  E Baraona; M A Leo; S A Borowsky; C S Lieber
Journal:  Science       Date:  1975-11-21       Impact factor: 47.728

8.  Early perivenular sclerosis in alcoholic fatty liver: an index of progressive liver injury.

Authors:  L Van Waes; C S Lieber
Journal:  Gastroenterology       Date:  1977-10       Impact factor: 22.682

9.  Effect of an intravenous infusion of ethanol on serum enzymes and lipids in patients with alcoholic liver disease.

Authors:  M Nishimura; Y Hasumura; J Takeuchi
Journal:  Gastroenterology       Date:  1980-04       Impact factor: 22.682

10.  Pathogenesis of alcohol-induced accumulation of protein in the liver.

Authors:  E Baraona; M A Leo; S A Borowsky; C S Lieber
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.